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Abstract: Randomized trials in acute promyelocytic leukemia patients have shown that treatment 
with a combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) is superior in 
efficacy to monotherapy, with significantly decreased mortality. So far, there are little data available 
to explain the success of the ATRA and ATO combination treatment in molecular terms. We showed 
that ATRA- and ATO-treated cells had the same capacity for superoxide production, which was 
reduced by two-thirds in the combined treatment. Secreted inflammatory biomarkers (monocyte 
chemoattractant protein-1 [MCP-1], interleukin-1 beta [IL-1β] and tumor necrosis factor-α [TNF-α]) 
were significantly decreased and were further reduced in a transglutaminase 2 (TG2) expression-
dependent manner. The amount of secreted TNF-α in the supernatant of NB4 TG2 knockout cells 
was close to 50 times lower than in ATRA-treated differentiated wild-type NB4 cells. The 
irreversible inhibitor of TG2 NC9 not only decreased reactive oxygen species production 28-fold, 
but decreased the concentration of MCP-1, IL-1β and TNF-α 8-, 15- and 61-fold, respectively in the 
combined ATRA + ATO-treated wild-type NB4 cell culture. We propose that atypical expression of 
TG2 leads to the generation of inflammation, which thereby serves as a potential target for the 
prevention of differentiation syndrome. 
Keywords: acute promyelocytic leukemia; all-trans retinoic acid (ATRA); arsenic trioxide (ATO), 
ATRA and ATO combination treatment; NB4 
 
1. Introduction 
Acute promyelocytic leukemia (APL) is characterized by the presence of a chromosomal 
translocation between the retinoic acid receptor-alpha (RARα) gene on chromosome 17 and the 
promyelocytic leukemia protein (PML) gene on chromosome 15, resulting in the PML-RARα fusion 
gene. The PML-RARα oncoprotein acts as an abnormal retinoid receptor, repressing transcription 
and resulting in the suppression of retinoic acid-induced myeloid differentiation. All-trans retinoic 
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acid (ATRA) both activates the PML-RARα chimera protein and initiates its proteolysis, resulting in 
the differentiation of APL leukemic cells [1–3]. 
In the 2000s, arsenic trioxide (As2O3/ATO) was approved by the Food and Drug Administration 
(US FDA) to treat APL. Clinical data have shown that ATO, either as a single agent or combined with 
ATRA, can improve the outcomes in newly diagnosed and relapsed APL, compared to ATRA 
treatment alone [4–6]. 
When combined with ATRA and chemotherapy, ATO can induce complete remission of APL 
patients, with a five-year overall survival rate up to 90% [5]. At the molecular level, ATO exhibits 
cytotoxic effects in a concentration-dependent manner, while at lower concentrations (< 0.5 μM), ATO 
can induce partial differentiation and at higher concentrations (> 0.5 μM), it initiates apoptosis of APL 
cells. Some of the signal transduction pathways and transactivations of transcription factors involved 
are arsenic-induced and redox-sensitive. These include the mitogen-activated protein kinases 
(MAPKs), extracellular signal-regulated kinases 1/2 (ERK1/2), stress-activated protein kinase/Jun-N 
terminal protein kinases (SAPK/JNK), the apoptosis signal-regulating kinase 1/thioredoxin 
(ASK1/TRX) system, the AKT-mTOR pathway, transcription factor AP-1 and the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) [7]. Although both ATO and ATRA prime 
the PML-RARα oncoprotein for proteolysis, only ATO is effective as a monotherapy, through the 
elimination of residual leukemia-initiating cells. The major limitation to ATO treatment is 
coagulopathy, which is one of the major causes of early death in APL, driven by procoagulant and 
fibrinolytic factors [8]. 
TG2 is a member of the transglutaminase family of enzymes, ubiquitously expressed in various 
organs. It may be localized intracellularly or extracellularly. In the absence of Ca2+, TG2 acts as a G-
protein (Ghα), a protein disulfide isomerase or a scaffold protein. In the presence of Ca2+, TG2 
catalyzes protein crosslinking by its Ca2+-dependent transamidation activity [9–13]. 
Under pathological conditions, elevated TG2 activity is thought to promote various disease 
states. The TG2 level is markedly increased in tumor cell lines, and its expression is associated with 
increased metastasis and drug resistance [14,15]. TG2 can drive the epithelial-mesenchymal transition 
and plays an essential role in the acquisition of cancer stem-cell traits [11,16]. Several studies have 
been published on the cell death and survival properties of TG2. The pro-apoptotic effects of TG2 are 
associated with the calcium-dependent protein–protein cross-linking activity at high calcium levels. 
In its survival-promoting attribution, TG2 most often participates as a protein–protein interaction 
partner in GTP-bound form [17,18]. In earlier studies, others tested a novel irreversible TG2 inhibitor 
NC9 to identify agents that can selectively target cancer stem cells in tumors [13,19,20]. Our studies 
demonstrated that elevated protein expression of TG2 could lead to inflammatory reactions [20,21]. 
During ATRA induced differentiation of the NB4 acute promyelocytic human leukemia cell lines 
TG2 is mainly expressed in the cytosol and is partly translocated to the cell nucleus [20,22]. We 
previously demonstrated the correlation of the expression levels of TG2 and inflammatory cytokines 
with differentiation syndrome (DS) [20,23]. 
DS, which develops in approximately 5–25% of patients, is a severe life-threatening condition 
triggered by the release of inflammatory cytokines, such as tumor necrosis factor α (TNF-α), 
interleukin-1β (IL-1β) and chemokines like monocyte chemoattractant protein-1 (MCP-1) (CCL2) [24]. 
These cytokines and chemokines are released from neoplastic promyelocytes as they differentiate in 
response to both ATRA and/or ATO therapy. Endothelium damage with a capillary leak, edema, 
hypotension, fever, rash and dyspnea, pulmonary infiltrates, pleural or pericardial effusions and 
tissue infiltration may ensue [24]. In the last decade, dexamethasone or prednisolone prophylaxis has 
been used for the prevention of DS during the remission induction phase, but it is ineffective in 
reducing mortality developing from DS [25]. 
We also previously demonstrated that shRNA-mediated knock-down or genomic deletion of 
TG2 in differentiating NB4 cell lines can decrease the levels of chemokines and cytokines, whose 
production is involved in the development of DS [20,23]. As a diminished expression of TG2 in 
differentiating APL cells may attenuate the ATRA-induced systemic inflammatory response 
syndrome in DS, we further investigated the role of TG2 in limiting toxicities arising from DS. NC9 
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is a TG2-selective irreversible inhibitor that blocks the enzyme active site and locks TG2 in an open 
conformation, thereby abrogating GTP binding as well. [11,17]. Our results showed that inhibition of 
TG2 by NC9 in ATRA + ATO combined treatment significantly reduces not just reactive oxygen 
species (ROS) but also proinflammatory cytokines and chemokine production that significantly 
increases the severity of DS. 
2. Results 
2.1. ATO Alters the Cellular Morphology of Differentiating NB4 Cells 
Several clinical studies have reported that the morphology of APL cells changed upon ATRA or 
ATO treatments. Apoptotic and necrotic cells appeared after ATO-induced cell death, exhibiting a 
variable size and quality of cytoplasm [26]. 
To determine the differentiation stages of NB4 cells, a variety of morphological changes were 
evaluated for the single and the combined treatments. In the case of ATRA treatment, the cells mainly 
represent differentiated and mitotic cells (blue and green triangles, Figure 1A). ATRA, ATO 0.5 μM 
and the combination treatment caused less apoptosis in NB4 WT and NB4 TG2-C (virus control) cells, 
such as TG2-deficient NB4 TG2-KD and NB4 TG2-KO cells (Figure 1B1,2, upper panels, green and 
black bars). Results showed that at day 5, arsenic trioxide induces a time- and dose-dependent 
cytotoxic effect on morphology, representing damaged and late apoptotic-necrotic phases. Higher 
concentrations of ATO were associated with an increased number of apoptotic and necrotic cells 
(Figure 1B1,2, lower panels, green and black bars). While the number of differentiated cells was low 
in NB4 WT and NB4 TG2-C cell lines, a higher apoptotic rate was seen in the ATRA + ATO 2.0 μM 
combined treatment compared to the ATRA + ATO 0.5 μM treatment of cells (Figure 1B2, upper 
panels). There was a higher degree of apoptosis or necrosis in NB4 TG2-KD or NB4 TG2-KO cells 
(Figure 1B2, upper panel, black and dark grey bars). ATO treatment alone resulted in minor 
differentiation, with ATO concentration-dependent apoptosis in the NB4 cell lines (Figure 1B1,B2, 
lower panels). 
 
Figure 1. Tissue transglutaminase (TG2) expression moderates arsenic-induced apoptosis. (A) TG2 
has a protective role against ATO-induced cell death, whereas its absence generates a more sensitive 
response to the treatment. Representative images of May–Grünwald–Giemsa staining for 
morphological examination of NB4 cell lines treated with 1 μM ATRA or with ATRA + ATO (0.5 or 
2.0 μM) for three and five days (n = 5). Light microscopic images and documentation were obtained 
using the FLoid® Cell Imaging Station instrument (Life Technologies). Cell death features are marked 
with different triangles based on the color code listed in the lower panel. (B1–B2) Quantification of 
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May–Grünwald–Giemsa-stained Cytospin™ slides. From each Cytospin slide, 200 cells treated with 
ATRA or ATO for five days (from 0.1 μM up to 2.5 μM) or in a combination thereof were counted 
from three different fields of view, were quantified based on cell death features listed and were 
marked with different colors at the right side of the panels. The graphs represent the mean values of 
the counted cells, where the black/grey/orange colors mark the cell death features. In NB4 WT and 
TG2-C cells, ATRA-induced high TG2 levels were associated with lower cell death ratios compared 
to the TG2-KD or TG2-KO cells. Vehicle controls are in the supplement (Figure S1). Statistical 
significance was determined via two-way analysis of variance (ANOVA; Bonferroni post-hoc test; 
ATRA + ATO 2.0 WT: Apoptotic vs. ATRA + ATO 2.0 KO: Apoptotic ****p < 0,0001; ATRA + ATO 0.5 
WT: Apoptotic vs. ATRA + ATO 0.5 KO: Apoptotic ****p < 0.0001). 
2.2. ATRA + ATO Combined Treatment Decreases Differentiated NB4 Cells’ Ability to Produce ROS 
We previously reported that the atypical expression of TG2 greatly enhances neutrophil 
granulocytes’ production of ROS by enhancing the expression of two important components of the 
NADPH-oxidase complex, NCF-2/P67PHOX and GP91PHOX. ATO treatment caused significant 
cellular changes in NB4 cell lines, which may affect the production of ROS. Because the NADPH-
oxidase system is responsible for ROS production, we sought to determine the extent of ROS 
production after ATRA/ATO treatments. Both NCF-2/P67PHOX and GP91PHOX mRNA expression 
levels were measured at 1 μM ATRA, 0.5 μM, 2.0 μM ATO, respectively, and ATRA + ATO combined 
treatments at days 0, 3 and 5. While the levels of mRNS expression of both genes showed a similar 
pattern, especially on the fifth day, displaying a TG2-dependent expression after ATRA treatment, 
ATO treatments resulted in a magnitude of gene expression almost similar to that of ATRA generated 
in NB4 WT cells (Figure 2A1,2; B1,2, left side). In combined treatments (ATRA + ATO, 0.5 and 2.0 
μM), as a consequence both of the combined treatment and the extent of TG2 quantities, expression 
values remained low compared to ATRA or ATO treatments alone (Figure 2A3,4; B3,4, right side). 
These expression values were also reflected in the production of ROS, especially in the ATRA + ATO 
2.0 μM treatment, where a 1/3 ROS generating capacity was measured compared to the ROS 
production with ATRA or ATO treatment alone, depending on the amount of TG2 (Figure 2C1–4). 
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Figure 2. Combined ATRA + ATO treatment attenuates both expression of NCF2 and GPPHOX91 
respiratory burst oxidase genes and the production of reactive oxygen species. (A1–A4) NB4 WT, 
Table. TG2-KD and TG2-KO cells were incubated with 1 μM ATRA, ATO (0.5 μM or 2.0 μM) and a 
combination of the two (A3–A4) for three (A1) and for five days (A2). Relative mRNA expressions of 
NCF2/P67PHOX were measured on the indicated days by real-time Q-PCR and were normalized to 
GAPDH. The graph represents relative mRNA expression (means ± SD, n = 3). Statistical significance 
was determined via two-way analysis of variance (ANOVA; Bonferroni post-hoc test; NB4 WT vs. 
TG2-KD, TG2-KO *p < 0.05, **p< 0.01 and ***p < 0.001, ****p < 0.0001). (B1–B4) NB4 WT, TG2-C, TG2-
KD and TG2-KO cells were incubated with 1 μM ATRA, ATO (0.5 μM or 2.0 μM) and a combination 
of the two (B3–B4) for three (B1) and for five days (B2). Relative mRNA expressions of GPPHOX91 
were measured on the indicated days by real-time Q-PCR and were normalized to GAPDH. The graph 
represents relative mRNA expression (means ± SD, n = 3). Statistical significance was determined via 
two-way analysis of variance (ANOVA; Bonferroni post-hoc test; NB4 WT vs. TG2-KD, TG2-KO *p < 
0.05, **p < 0.01 and ***p < 0.001, ****p < 0.0001). (C1–C4) NB4 WT, TG2-C, TG2-KD and TG2-KO cells 
were incubated with 1 μM ATRA, ATO (0.5 μM or 2.0 μM) and a combination of the two (C3–C4) for 
three (C1) and for five days (C2). Production of ROS was determined for each cell line after the 
mentioned treatments, using a luminescence-based method in triplicate (n = 5), and was reported as 
RLUs. Graphs are the representation of mean ± SD values normalized to 100 μg protein of cell lysate 
content. Vehicle controls are in the supplement (Figure S2). Statistical significance was determined 
via two-way analysis of variance (ANOVA; Bonferroni post-hoc test; NB4 WT vs. TG2-KD, TG2-KO 
*p < 0.05, **p < 0.01 and ***p < 0.001, ****p < 0.0001). 
2.3. Combined ATRA + ATO Treatment Markedly Reduces Inflammatory Biomarker Expression 
DS, which can be fatal in 2.5–30% of cases in its moderate or severe forms, is characterized by 
the presence of a large number of inflammatory, differentiated leukemic cells in the bloodstream that 
synthesize and secrete chemokines and cytokines, triggering a so-called “cytokine storm.” We 
previously showed that MCP-1, IL-1β and TNFα were secreted in a TG2-quantity-dependent manner 
in differentiated NB4 cell lines. MCP-1, IL-1β and TNFα were measured at the mRNA and protein 
levels in ATRA, ATRA + ATO 0.5 μM, and ATRA + ATO 2.0 μM differentiated NB4 WT, NB4 TG2-
C, NB4 TG2-KD and NB4 TG2 KO-cell culture systems. Overall, at day 5, mRNA levels of MCP-1, IL-
1β and TNFα were approximately 50% lower for the combined ATRA + ATO 2.0 μM treatment than 
for ATRA, but these values were further reduced in a TG2-quantity-dependent manner (Figure 
3A1,B1,C1). At day 5, we observed the effective inhibition of MCP-1, IL-1β and TNFα (with 5×, 10× 
and 20× lower values, respectively, than the controls) in the case of NB4 WT cells in combined 
therapy, especially ATRA + ATO 2.0 μM, with respect to proinflammatory cytokines and the 
chemokine content of cell culture supernatants. These values were further reduced in a TG2-quantity-
dependent manner (Figure 3A2,B2,C2, Table S1). 
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Figure 3. Combined ATRA + ATO treatment can reduce the MCP-1, IL-1β and TNFα inflammatory 
biomarkers. (A1,B1,C1) NB4 WT, TG2-C, TG2-KD and TG2-KO cells were incubated with 1 μM ATRA 
(left panel), ATO (0.5 μM or 2.0 μM) and a combination of the two (middle and right panels) for three 
and for five days. Relative mRNA expressions of MCP-1 (A1), IL-1β (B1) and TNFα (C3) were 
measured on the indicated days by real-time Q-PCR and were normalized to GAPDH. The graph 
represents relative mRNA expression (means ± SD, n = 3). Statistical significance was determined via 
Cancers 2020, 12, 648 7 of 13 
two-way analysis of variance (ANOVA; Bonferroni post-hoc test; NB4 WT vs. TG2-KD, TG2-KO *p < 
0.05, **p < 0.01 and ***p < 0.001, ****p < 0.0001). (A2,B2,C2) The protein content of the supernatants of 
NB4 cell lines was quantified by ELISA and was normalized to 100 μg protein content of NB4 cell 
lysates. The secreted protein levels of MCP-1 (A2), IL-1β (B2) and TNFα (C2) from three independent 
experiments were measured in triplicate and represent the mean ± SD values. Vehicle controls are in 
the supplement (Figure S3,S4). Statistical significance was determined via two-way analysis of 
variance (ANOVA; Bonferroni post-hoc test; NB4 WT vs. TG2-KD, TG2-KO * p < 0.05, ** p < 0.01 and 
*** p < 0.001, ****p < 0.0001). 
2.4. TG2 Inhibitor NC9 eradicates the Capability of ATRA + ATO-Differentiated NB4 Cells for ROS and 
Inflammatory Biomarker Production 
NC9 is an irreversible TG2 inhibitor, and ATO-induced differentiation is a TG2-independent 
process. In cell lines where TG2 was induced by ATRA, significantly lower expression levels of both 
NCF-2/P67PHOX and GP91PHOX mRNA were measured in the presence of NC9, compared to the 
controls (Figure 4A1–3; B1–3, red bars, black bars as control). For NCF-2/P67PHOX, the measured 
values were less than those measured for ATRA in the presence of TG2 inhibitor NC9 (Figure 4A1–
3). In ATRA + ATO-treated cells (0.5 and 2.0 μM), TG2 inhibitor NC9 significantly reduced ROS 
production at day 5 in an ATO concentration-dependent manner (Figure 4C1–3). The ROS production 
of differentiated NB4 WT cells was decreased 2.4- and 3.5-fold by 0.5 μM and 2.0 μM ATO, 
respectively. The TG2 inhibitor NC9 further reduced these values to 2.5 times for the ATRA, 10 times 
for the ATRA + ATO 0.5 μM and 28 times for the ATRA + ATO 2.0 μM treatments (Figure 4C1–3). 
 
Figure 4. The TG2 inhibitor NC9 diminishes the capability of ATRA + ATO-differentiated NB4 WT 
cell lines for ROS production. (A1–A3) Relative mRNA expressions of NCF-2/P67PHOX and 
GP91PHOX (B1–B3) were measured in NB4 WT, TG2-C, TG2-KD and TG2-KO cells treated with 
ATRA + NC9, with ATRA + ATO 0.5 μM + NC9 and with ATRA + ATO 2.0 μM + NC9 at the indicated 
time points by Q-PCR, and they were normalized to GAPDH (black bars as control, without NC9). 
The mRNA expression levels from three independent experiments were measured in triplicate, and 
graphs show the representation of the mean ± SD values. Statistical significance was determined via 
Cancers 2020, 12, 648 8 of 13 
two-way analysis of variance (ANOVA; Bonferroni and Tukey post-hoc test; ATRA vs. ATRA+NC9 * 
p < 0.05, ** p < 0.01 and *** p < 0.001, ****p < 0.0001). (C1–C3) In the presence of 30 μM of the TG2 
inhibitor NC9, production of ROS was determined for each cell line using a luminescence-based 
method in triplicate (n = 5) and reported in Relative Luminescence Units RLUs without NC9 (black 
bars as control). Graphs are the representation of mean ± SD values normalized to 100 μg protein of 
cell lysate content. Statistical significance was determined via two-way analysis of variance (ANOVA; 
Bonferroni and Tukey post-hoc test; ATRA vs. ATRA+NC9 * p < 0.05, ** p < 0.01 and *** p < 0.001, **** 
p < 0.0001). 
Since the levels of TG2 expression altered the expression and secretion levels of MCP-1, IL-1β 
and TNFα inflammatory biomarkers in NB4 WT, NB4 TG2-C, NB4 TG2-KD and NB4 TG2-KO cells 
after the combined treatment with ATRA + ATO (0.5 and 2.0 μM) (Figure 5A2,B2,C2), it seemed 
reasonable to investigate the effect of TG2 inhibitor NC9 on differentiating NB4 WT cells using the 
combined ATRA + ATO (0.5 and 2.0 μM) treatment. At day 5, we found that it significantly reduced 
the quantities of both mRNA and protein of MCP-1, IL-1β and TNF-α in cells and supernatants, 
especially in the case of TNF-α, compared to results from a single ATRA treatment (Figure 5A1–B3, 
red bars, Table S2.) 
 
Figure 5. Inhibition of TG2 decreases the gene expression and the protein secretion of TNF-α, IL-1β 
and MCP-1 in differentiated NB4 cells. Relative mRNA expressions of MCP-1 (A1), IL-1β (A2) and 
TNF-α (A3) were measured in ATRA and in ATRA + ATO (0.5 or 2.0 μM) in differentiated NB4 cell 
lines with or without 30 μM NC9 (red bars, black bars as control) on the indicated days by Q-PCR 
and were normalized to GAPDH. The mRNA expression levels from three independent experiments 
were measured in triplicate, and the graphs show the representation of the mean ± SD values. 
Statistical significance was determined via two-way analysis of variance (ANOVA; Bonferroni and 
Tukey post-hoc test; ATRA vs. ATRA+NC9 *p < 0.05, ** p < 0.01 and *** p < 0.001, **** p < 0.0001). The 
protein content of the supernatants of MCP-1 (B1), IL-1β (B2) and TNFα (B3) with or without 30 μM 
NC9 (red bars, black bars as control) were quantified by ELISA and were normalized to 100 μg protein 
content of NB4 WT cell lysates. The figures show secreted protein levels from three independent 
experiments measured in triplicate, and the graphs show the representation of the mean ± SD values. 
Statistical significance was determined via two-way analysis of variance (ANOVA; Bonferroni and 
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Tukey post-hoc test; ATRA vs. ATRA+NC9 * p < 0.05, ** p < 0.01 and *** p < 0.001, **** p < 0.0001). 
Relative changes of MCP-1 (C1), IL-1β (C2), TNFα (C3) and ROS (C4) production in the presence of 
NC9 related to ATRA-only treatment in NB4 WT cells. Changes were calculated from values of ATRA 
only and ATRA + NC9, from ATRA + ATO 0.5 μM + NC9 and from ATRA + ATO 2.0 μM NC9 
treatments. Graphs represent the changes compared to a single ATRA treatment. 
3. Discussion 
ATRA-based therapy is frequently used in the clinical treatment of APL patients, which leads to 
the terminal differentiation of leukemic cells towards the neutrophil granulocyte stage. 
Hyperinflammatory reactions may constitute severe side effects of ATRA treatment, including the 
infiltration and damaging of soft tissues and organs, such as the lungs and heart, by differentiating 
APL cells that produce reactive oxygen species. ATRA-induced differentiation of APL cells could 
generate increased secretion of cytokines, chemokines and interleukins as well as cell adhesion and 
migration. ATRA-induced differentiation is also associated with the elevated expression of two 
components of the NADPH-oxidase complex, NCF-2/P67PHOX and GP91PHOX, resulting in the 
possibility of increased ROS production and, consequently, more severe organ damage. 
It has previously been reported that the morphology of APL cells changed upon ATRA or ATO 
treatment. ATO treatment was associated with apoptotic or necrotic cell death, exhibiting variable 
size and quality of cytoplasm [26]. Notably, reduced or absent TG2 enhanced the sensitivity of NB4 
cells to a combined ATRA + ATO 2.0 μM treatment, with significantly higher apoptotic and necrotic 
rates. 
Oxidative stress caused by reactive oxygen species, a group of oxygen-based reactive molecules 
produced by ATO activated the NADPH-oxidase system, resulting in the disruption of mitochondrial 
membrane potential and subsequent apoptosis [27–29]. As published previously, the mRNA 
expression of NCF2/P67PHOX and GPPHOX91 were substantially higher in the presence of TG2 
compared to NB4 TG2-KD and TG2-KO cells. Here we find that ATO alone can trigger an increase in 
the amount of mRNA of NCF2 and GPPHOX91 as well as the production of ROS, similar to ATRA 
in differentiated NB4 cell lines. So far, no study has shown a 2-fold decrease in ROS production in 
response to combined ATRA + ATO compared to single ATRA or ATO treatments. While amounts 
of atypically expressed TG2 in differentiated NB4 cell lines can enhance the function of the NAPDH-
oxidase system, leading to high ROS production, TG2 deficiency in TG2-KD cells or TG2-KO cells is 
associated with significantly lower ROS production, which may be further reduced by the combined 
ATO treatments. 
Resting neutrophil granulocytes can be activated by cytokines, chemokines, interleukins 
(inflammatory biomarkers) or integrin-mediated signaling processes. Similarly, differentiating or 
mature NB4 cells synthesize and secrete cytokines, chemokines or interleukins induced by ATRA 
treatment [20,23,24,30]. In APL, differentiating APL cells stimulate their own extravasation and 
migration into various organs by producing inflammatory cytokines, chemokines and interleukins 
(MCP-1, IL-1β, TNF-α) in an autocrine mechanism. 
Compared to ATRA treatment, combining ATRA with ATO reduced both mRNA expression 
and the concentration of secreted MCP-1, IL-1β and TNF-α in a time-dependent manner (Figure 
3A2,B2,C2). The decreases directly correlated with both TG2 expression and ATO concentration. The 
NC9 TG2 inhibitor significantly reduced the mRNA levels of NCF-2/P67PHOX, GP91PHOX, MCP-1, 
IL-1β and TNF-α and also reduced the production of ROS and secreted levels of MCP-1, IL-1β and 
TNFα (Figure 4A1–C3; Figure 5A1–3, B1–3, red bars). The amount of secreted proteins was reduced 
significantly (to a 7- to 60-fold decrease) after the combined ATRA + ATO treatment compared to the 
ATRA treatment alone (Table S1). 
We have previously shown that the TG2 inhibitor NC9 decreases NF-κB translocation to the 
nucleus and NF-κB transcriptional activity as well as significantly reducing the production of 
inflammatory biomarkers, such as MCP-1, IL-1β and TNF-α [20]. Accordingly, our current study 
demonstrates that combined ATRA + ATO (2.0 μM) with an inhibition of atypically expressed TG2 
by NC9 radically limits the expression and secretion concentration of three inflammatory biomarkers 
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and radical oxygen species (Figure 5C1–4). ATRA + ATO (2μM) + NC9 treatment resulted in an 8-
fold decrease in MCP-1, a 15-fold decrease in IL-1β levels and a 61-fold suppression of TNFα; there 
was also a 28-fold reduction in ROS production, compared to ATRA alone, at day 5. 
4. Materials and Methods 
4.1. Cell Cultures and Treatments 
NB4 cells sublines NB4 TG2-C (virus control containing scrambled shRNA [23], TG2-deficient 
NB4 TG2-KD (shRNA based knockdown) [23] and NB4 TG2-KO cells (TALEN TG2 knockout) [20] 
were maintained in RPMI-1640 medium containing 10% fetal bovine serum (Life technologies, Van 
Allen Way, Carlsbad, CA 92008, United States), 2 mM L-glutamine (Sigma Aldrich, St. Louis, 
Missouri United States) and 100 μg/mL penicillin-streptomycin solution (Sigma Aldrich). Cells were 
differentiated in the presence of 1 μM ATRA (Sigma Aldrich). For combined treatments, 1 μM ATRA 
with either 0.5 μM or 2.0 μM ATO solutions were prepared (Sigma Aldrich). For TG2 inhibitory 
treatment, NC9 was used at 30 μM final concentration (Stock concentration: 30 mM). Cells were 
incubated at 37 °C with 5% CO2. Treatments lasted 0–5 days. Other compounds and solutions were 
used as listed in the Online Table S3. 
4.2. Cytospin 
Samples were taken from a homogeneous suspension of cell cultures. After pre-cleaning the 
slides (70% alcohol), 10 μL of a homogeneous sample together with 90 μL of 1x phosphate-buffered 
saline was applied to the Cytospin™ tube (Shandon CYTOSPIN II, 6511 Bunker Lake Blvd. Ramsey, 
MN 55303 USA), followed by centrifugation at 800 rpm for 3 min. Samples were then fixed at room 
temperature with methanol and were prepared for further staining. 
4.3. May-Grünwald Giemsa Staining 
May–Grünwald and Giemsa solutions were diluted with distilled water at a 1:10 ratio. 
Previously fixed samples were stained with a May–Grünwald solution for 10 min and were then 
rinsed with a diluted Giemsa solution for 5–30 min. Slides were washed and dried at room 
temperature. Light microscope images and documentation were obtained using a FLoid® Cell 
Imaging Station instrument (Life Technologies) at a scale of 200 μm. The ratio of the undifferentiated, 
differentiated, apoptotic, necrotic and mitotic cells in NB4 cell lines was determined by 
morphological changes/features during the ATRA, ATO and combined ATRA + ATO treatments. 
Based on our morphological type evaluations, we classified the morphological types of ATRA-, ATO- 
and ATRA + ATO-differentiated NB4 cells into six groups: a, undifferentiated (unsegmented nuclear 
region and thin cytoplasmic region); b, differentiated (a segmented nuclear fraction with the white-
grey higher proportion of the cytoplasmic region); c, apoptotic (well-defined membrane changes, 
with shrinkage) and d: necrotic (lack of nuclear fraction with severe destruction of the membrane 
structure). Other groups, such as: e, apoptotic-necrotic (strong blue nuclear remnants, disarrayed 
membrane structure) and f, mitotic (chromatin changes, round shape) were also defined from the 
ATRA and ATO combined treatment. 
4.4. Gene Expression Analysis 
For Q-PCR measurements, total RNA samples were isolated by TRIzol reagent, following the 
company’s instructions. Total RNA was quantified by a NanoDrop 2000 Spectrophotometer (Thermo 
Fisher, Waltham, MA USA 02451). Each sample was diluted to 200 ng/μL concentration, followed by 
reverse transcription using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher) in a 
reaction of: 10 μL sample + 10 μL RT-Master mix. The assay and the PCR were performed according 
to the manufacturer's protocol. For the real-time Q-PCR reaction, the following TaqMan probes (ABI, 
Applied Biosystems, Waltham, MA USA 02451) were used: NCF2, GPPhox91, IL-1β, MCP-1, TNF-α 
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and GAPDH. The analysis was carried out using the ABI Prism 7900 (ABI, Applied Biosystems). 
Relative mRNA expression levels were normalized to the level of GAPDH using the ΔΔCt method. 
4.5. Superoxide Anion Production 
The amount of superoxide radicals was measured by luminol-chemiluminescence assay, using 
L-012 dye (Wako Pure Chemical Industries, Ltd., 1-2 Doshomachi 3-chome, Chuo-ku, Osaka, Japan) 
after PMA (50 nM) induction, in a reaction volume of 100 μL medium containing cells and L-012 (50 
μM) dye. After 5 min, samples were measured in a Synergy Multimode Microplate Reader (BioTek 
Instruments, Inc, Winooski, VT, USA). Production of generated light by the reaction was recorded in 
relative luminescence units (RLUs) and was corrected with the protein concentration levels of the 
samples. 
4.6. Statistical Analysis 
Statistical analysis was carried out using GraphPad Prism version 8.02, by two-way ANOVA 
(Bonferroni posthoc test; *p < 0.05, ** p < 0.01 and *** p < 0.001, **** p < 0.0001). 
5. Conclusions 
Together, these results suggest that the atypical expression level of TG2 in ATRA-induced 
differentiating APL cells is a crucial factor in developing inflammation and in the production of ROS. 
The lower expression of TG2 may effectively reduce the chance of inflammatory processes and organ 
damage. 
In the combined ATRA + ATO treatment of differentiating APL cells, ATO can restrict ATRA-
induced ROS and inflammatory biomarker production capacity in a dose-dependent manner. The 
irreversible inhibitor of TG2 NC9 not only decreased reactive oxygen species production 28-fold, but 
decreased the concentration of MCP-1, IL-1β and TNF-α 8-, 15- and 61-fold, respectively in the 
combined ATRA + ATO-treated wild-type NB4 cell culture. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Table S1: Protein 
content of supernatant of NB4 cell lines, Table S2: Protein content of supernatant of NB4 cell lines, Table S3: List 
of chemicals and reagents were used, Figure S1: Representative images of May-Grünwald-Giemsa staining, 
Figure S2: Production of ROS in vehicle treated NB4 cells, Figure S3: mRNA expression of MCP-1, IL-1β and 
TNFα inflammatory biomarkers , Figure S4: The protein content of the supernatants of NB4 cell lines was 
quantified by ELISA. 
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